|
1
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the Surveillance, Epidemiology, and End Results Program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jawad MU, Cheung MC, Clarke J, Koniaris LG
and Scully SP: Osteosarcoma: Improvement in survival limited to
high-grade patients only. J Cancer Res Clin Oncol. 137:597–607.
2011. View Article : Google Scholar
|
|
3
|
Bielack SS, Kempf-Bielack B, Delling G,
Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M,
Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma
of the extremities or trunk: An analysis of 1,702 patients treated
on neoadjuvant cooperative osteosarcoma study group protocols. J
Clin Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hegyi M, Semsei AF, Jakab Z, Antal I, Kiss
J, Szendroi M, Csoka M and Kovacs G: Good prognosis of localized
osteosarcoma in young patients treated with limb-salvage surgery
and chemotherapy. Pediatr Blood Cancer. 57:415–422. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Anderson ME: Update on survival in
osteosarcoma. Orthop Clin North Am. 47:283–292. 2016. View Article : Google Scholar
|
|
6
|
Zwaga T, Bovee JV and Kroon HM:
Osteosarcoma of the femur with skip, lymph node, and lung
metastases. Radiographics: A review publication of the Radiological
Society of North America Inc. 28:277–283. 2008. View Article : Google Scholar
|
|
7
|
Miller BJ, Cram P, Lynch CF and Buckwalter
JA: Risk factors for metastatic disease at presentation with
osteosarcoma: An analysis of the SEER database. J Bone Joint Surg
Am. 95:e892013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Narlik-Grassow M, Blanco-Aparicio C and
Carnero A: The PIM family of serine/threonine kinases in cancer.
Med Res Rev. 34:136–159. 2014. View Article : Google Scholar
|
|
9
|
Nawijn MC, Alendar A and Berns A: For
better or for worse: The role of Pim oncogenes in tumorigenesis.
Nat Rev Cancer. 11:23–34. 2011. View
Article : Google Scholar
|
|
10
|
Aguirre E, Renner O, Narlik-Grassow M and
Blanco-Aparicio C: Genetic modeling of PIM proteins in cancer:
Proviral tagging and cooperation with oncogenes, tumor suppressor
genes, and carcinogens. Front Oncol. 4:1092014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Alvarado Y, Giles FJ and Swords RT: The
PIM kinases in hematological cancers. Expert Rev Hematol. 5:81–96.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guo S, Mao X, Chen J, Huang B, Jin C, Xu Z
and Qiu S: Overexpression of Pim-1 in bladder cancer. J Exp Clin
Cancer Res. 29:1612010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Reiser-Erkan C, Erkan M, Pan Z, Bekasi S,
Giese NA, Streit S, Michalski CW, Friess H and Kleeff J:
Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in
pancreatic ductal adenocarcinoma. Cancer Biol Ther. 7:1352–1359.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Brault L, Gasser C, Bracher F, Huber K,
Knapp S and Schwaller J: PIM serine/threonine kinases in the
pathogenesis and therapy of hematologic malignancies and solid
cancers. Haematologica. 95:1004–1015. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nga ME, Swe NN, Chen KT, Shen L, Lilly MB,
Chan SP, Salto-Tellez M and Das K: PIM-1 kinase expression in
adipocytic neoplasms: Diagnostic and biological implications. Int J
Exp Pathol. 91:34–43. 2010. View Article : Google Scholar
|
|
16
|
Holder SL and Abdulkadir SA: PIM1 kinase
as a target in prostate cancer: Roles in tumorigenesis, castration
resistance, and docetaxel resistance. Curr Cancer Drug Targets.
14:105–114. 2014. View Article : Google Scholar
|
|
17
|
Warnecke-Eberz U, Bollschweiler E, Drebber
U, Metzger R, Baldus SE, Hölscher AH and Mönig S: Prognostic impact
of protein overexpression of the proto-oncogene PIM-1 in gastric
cancer. Anticancer Res. 29:4451–4455. 2009.PubMed/NCBI
|
|
18
|
Albertson DJ, Schmidt RL, Bearss JJ, Tripp
SR, Bearss DJ and Liu T: Patterns and significance of PIM kinases
in urothelial carcinoma. Appl Immunohistochem Mol Morphol.
23:717–723. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Peng YH, Li JJ, Xie FW, Chen JF, Yu YH,
Ouyang XN and Liang HJ: Expression of pim-1 in tumors, tumor stroma
and tumor-adjacent mucosa co-determines the prognosis of colon
cancer patients. PLoS One. 8:e766932013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mochizuki T, Kitanaka C, Noguchi K,
Muramatsu T, Asai A and Kuchino Y: Physical and functional
interactions between Pim-1 kinase and Cdc25A phosphatase.
Implications for the Pim-1-mediated activation of the c-Myc
signaling pathway. J Biol Chem. 274:18659–18666. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Morishita D, Katayama R, Sekimizu K,
Tsuruo T and Fujita N: Pim kinases promote cell cycle progression
by phosphorylating and down-regulating p27Kip1 at the
transcriptional and posttranscriptional levels. Cancer Res.
68:5076–5085. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang Y, Wang Z and Magnuson NS: Pim-1
kinase-dependent phosphorylation of p21Cip1/WAF1
regulates its stability and cellular localization in H1299 cells.
Mol Cancer Res. 5:909–922. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bachmann M, Kosan C, Xing PX, Montenarh M,
Hoffmann I and Möröy T: The oncogenic serine/threonine kinase Pim-1
directly phosphorylates and activates the G2/M specific phosphatase
Cdc25C. Int J Biochem Cell Biol. 38:430–443. 2006. View Article : Google Scholar
|
|
24
|
Yan B, Zemskova M, Holder S, Chin V, Kraft
A, Koskinen PJ and Lilly M: The PIM-2 kinase phosphorylates BAD on
serine 112 and reverses BAD-induced cell death. J Biol Chem.
278:45358–45367. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Aho TL, Sandholm J, Peltola KJ, Mankonen
HP, Lilly M and Koskinen PJ: Pim-1 kinase promotes inactivation of
the pro-apoptotic Bad protein by phosphorylating it on the Ser112
gatekeeper site. FEBS Lett. 571:43–49. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Santio NM, Salmela M, Arola H, Eerola SK,
Heino J, Rainio EM and Koskinen PJ: The PIM1 kinase promotes
prostate cancer cell migration and adhesion via multiple signalling
pathways. Exp Cell Res. 342:113–124. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Grundler R, Brault L, Gasser C, Bullock
AN, Dechow T, Woetzel S, Pogacic V, Villa A, Ehret S, Berridge G,
et al: Dissection of PIM serine/threonine kinases in
FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of
CXCL12-CXCR4-mediated homing and migration. J Exp Med.
206:1957–1970. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rainio EM, Sandholm J and Koskinen PJ:
Cutting edge: Transcriptional activity of NFATc1 is enhanced by the
Pim-1 kinase. J Immunol. 168:1524–1527. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bhattacharya N, Wang Z, Davitt C, McKenzie
IF, Xing PX and Magnuson NS: Pim-1 associates with protein
complexes necessary for mitosis. Chromosoma. 111:80–95. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Magnuson NS, Wang Z, Ding G and Reeves R:
Why target PIM1 for cancer diagnosis and treatment? Future Oncol.
6:1461–1478. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Arunesh GM, Shanthi E, Krishna MH, Sooriya
Kumar J and Viswanadhan VN: Small molecule inhibitors of PIM1
kinase: July 2009 to February 2013 patent update. Expert Opin Ther
Pat. 24:5–17. 2014. View Article : Google Scholar
|
|
32
|
Qian KC, Wang L, Hickey ER, Studts J,
Barringer K, Peng C, Kronkaitis A, Li J, White A, Mische S, et al:
Structural basis of constitutive activity and a unique nucleotide
binding mode of human Pim-1 kinase. J Biol Chem. 280:6130–6137.
2005. View Article : Google Scholar
|
|
33
|
Mikkers H, Nawijn M, Allen J, Brouwers C,
Verhoeven E, Jonkers J and Berns A: Mice deficient for all PIM
kinases display reduced body size and impaired responses to
hematopoietic growth factors. Mol Cell Biol. 24:6104–6115. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xie Y, Xu K, Linn DE, Yang X, Guo Z,
Shimelis H, Nakanishi T, Ross DD, Chen H, Fazli L, et al: The
44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes
its multimerization and drug-resistant activity in human prostate
cancer cells. J Biol Chem. 283:3349–3356. 2008. View Article : Google Scholar
|
|
35
|
Zemskova MY, Song JH, Cen B, Cerda-Infante
J, Montecinos VP and Kraft AS: Regulation of prostate stromal
fibroblasts by the PIM1 protein kinase. Cell Signal. 27:135–146.
2015. View Article : Google Scholar :
|
|
36
|
Cheng F, Weidner-Glunde M, Varjosalo M,
Rainio EM, Lehtonen A, Schulz TF, Koskinen PJ, Taipale J and Ojala
PM: KSHV reactivation from latency requires Pim-1 and Pim-3 kinases
to inactivate the latency-associated nuclear antigen LANA. PLoS
Pathog. 5:e10003242009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ionov Y, Le X, Tunquist BJ, Sweetenham J,
Sachs T, Ryder J, Johnson T, Lilly MB and Kraft AS: Pim-1 protein
kinase is nuclear in Burkitt's lymphoma: Nuclear localization is
necessary for its biologic effects. Anticancer Res. 23A:167–178.
2003.
|
|
38
|
Brault L, Menter T, Obermann EC, Knapp S,
Thommen S, Schwaller J and Tzankov A: PIM kinases are progression
markers and emerging therapeutic targets in diffuse large B-cell
lymphoma. Br J Cancer. 107:491–500. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhu X, Xu JJ, Hu SS, Feng JG, Jiang LH,
Hou XX, Cao J, Han J, Ling ZQ and Ge MH: Pim-1 acts as an oncogene
in human salivary gland adenoid cystic carcinoma. J Exp Clin Cancer
Res. 33:1142014. View Article : Google Scholar
|
|
40
|
Yang Q, Chen LS, Neelapu SS, Miranda RN,
Medeiros LJ and Gandhi V: Transcription and translation are primary
targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
Blood. 120:3491–3500. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Quan J, Zhou L and Qu J: Knockdown of
Pim-3 suppresses the tumorigenicity of glioblastoma by regulating
cell cycle and apoptosis. Cell Mol Biol. 61:42–50. 2015.PubMed/NCBI
|
|
42
|
Wang Z, Cao CJ, Huang LL, Ke ZF, Luo CJ,
Lin ZW, Wang F, Zhang YQ and Wang LT: EFEMP1 promotes the migration
and invasion of osteosarcoma via MMP-2 with induction by AEG-1 via
NF-κB signaling pathway. Oncotarget. 6:14191–14208. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lu XY, Lu Y, Zhao YJ, Jaeweon K, Kang J,
Xiao-Nan L, Ge G, Meyer R, Perlaky L, Hicks J, et al: Cell cycle
regulator gene CDC5L, a potential target for 6p12-p21 amplicon in
osteosarcoma. Mol Cancer Res. 6:937–946. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liao Y, Feng Y, Shen J, Gao Y, Cote G,
Choy E, Harmon D, Mankin H1, Hornicek F1 and Duan Z1: Clinical and
biological significance of PIM1 kinase in osteosarcoma. J Orthop
Res. 34:1185–1194. 2016. View Article : Google Scholar
|
|
45
|
Gurney J, Swensen A and Bulterys M:
Malignant bone tumors. Cancer Incidence and Survival Among Children
and Adolescents: United States SEER Program 1975–1995. National
Cancer Institute, SEER Program; Ries L, Smith M, Gurney J, Linet M,
Tamra T, Young J and Bunin G: Bethesda, MD: NIH Pub. No. 99-4649;
pp. 99–110. 1999
|
|
46
|
Wagle S, Park SH, Kim KM, Moon YJ, Bae JS,
Kwon KS, Park HS, Lee H, Moon WS, Kim JR, et al: DBC1/CCAR2 is
involved in the stabilization of androgen receptor and the
progression of osteosarcoma. Sci Rep. 5:131442015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kim JH, Kim WS, Yun Y and Park C:
Epstein-Barr virus latent membrane protein 1 increases
chemo-resistance of cancer cells via cytoplasmic sequestration of
Pim-1. Cell Signal. 22:1858–1863. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Santio NM, Vahakoski RL, Rainio EM,
Sandholm JA, Virtanen SS, Prudhomme M, Anizon F, Moreau P and
Koskinen PJ: Pim-selective inhibitor DHPCC-9 reveals Pim kinases as
potent stimulators of cancer cell migration and invasion. Mol
Cancer. 9:2792010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ren K, Duan W, Shi Y, Li B, Liu Z and Gong
J: Ectopic over-expression of oncogene Pim-2 induce malignant
transformation of nontumorous human liver cell line L02. J Korean
Med Sci. 25:1017–1023. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhuang H, Zhao MY, Hei KW, Yang BC, Sun L,
Du X and Li YM: Aberrant expression of PIM-3 promotes proliferation
and migration of ovarian cancer cells. Asian Pac J Cancer Prev.
16:3325–3331. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Narlik-Grassow M, Blanco-Aparicio C,
Cecilia Y, Peregrina S, Garcia-Serelde B, Muñoz-Galvan S, Cañamero
M and Carnero A: The essential role of PIM kinases in sarcoma
growth and bone invasion. Carcinogenesis. 33:1479–1486. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Decker S, Finter J, Forde AJ, Kissel S,
Schwaller J, Mack TS, Kuhn A, Gray N, Follo M, Jumaa H, et al: PIM
kinases are essential for chronic lymphocytic leukemia cell
survival (PIM2/3) and CXCR4-mediated microenvironmental
interactions (PIM1). Mol Cancer Ther. 13:1231–1245. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Santio NM, Eerola SK, Paatero I,
Yli-Kauhaluoma J, Anizon F, Moreau P, Tuomela J, Härkönen P and
Koskinen PJ: Pim kinases promote migration and metastatic growth of
prostate cancer xenografts. PLoS One. 10:e01303402015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Oda Y, Yamamoto H, Tamiya S, Matsuda S,
Tanaka K, Yokoyama R, Iwamoto Y and Tsuneyoshi M: CXCR4 and VEGF
expression in the primary site and the metastatic site of human
osteosarcoma: analysis within a group of patients, all of whom
developed lung metastasis. Mod Pathol. 19:738–745. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Laverdiere C, Hoang BH, Yang R, Sowers R,
Qin J, Meyers PA, Huvos AG, Healey JH and Gorlick R: Messenger RNA
expression levels of CXCR4 correlate with metastatic behavior and
outcome in patients with osteosarcoma. Clin Cancer Res.
11:2561–2567. 2005. View Article : Google Scholar : PubMed/NCBI
|
